Clinical trials: Old Age; Dementia
Healthy, Alzheimer Disease
A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease
The purpose of this study is to investigate changes of cerebral spinal fluid (CSF) proteins over time using continuous CSF sampling for 36 hours in elderly healthy volunteers and volunteers with mild cognitive impairment or…
- Trial name
- NCT01436188
- Testing
- Standard CSR sampling procedure, Alternate frequency CSR sampling procedure, Standard frequent CSR sampling procedure with 800 mg ibuprofen
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease
Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy
The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease…
- Trial name
- NCT00499200
- Testing
- SRA-444
- Where
- Sweden
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
This study will evaluate the performance characteristics of a novel [18F] amyloid detection ligand (18F]-AV-45) with respect to its ability to distinguish patients with clinically-diagnosed probable Alzheimer's disease from…
- Trial name
- NCT00855868
- Testing
- florbetapir F 18, [11C]-PIB
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531
The main objectives of this study is to assess the safety and tolerability of ascending single and multiple oral doses of SAM-531 in healthy subjects
- Trial name
- NCT00726115
- Testing
- SAM-531
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Falls (Accidents) in Old Age
FallsTalk Falls Prevention Program for Caregivers and Persons With Memory Loss or Dementia
This randomized-control trial involves dyads consisting of a family caregiver (CG) and a person with memory loss or dementia (PwD).
- Trial name
- FT-C (NCT03961386)
- Testing
- FallsTalk-C, FallsTalk
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Brookside Research & Development Company
Alzheimer Disease, Cognitive Decline
Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease
The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly developed computerized cognitive tests.
- Conditions
- Alzheimer Disease, Cognitive Decline, Aging
- Trial name
- NCT04800588
- Testing
- California Cognitive Assessment Battery
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Neurobehavioral Systems, Inc.
Healthy Subjects
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
- Trial name
- NCT02509117
- Testing
- PF-06751979 single ascending dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Behavioral and Psychiatric Symptoms of Dementia
The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)
The aim of this study is to retrospectively evaluate and describe the use of antipsychotics among participants enrolled in the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.
- Trial name
- NCT03692182
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Tabula Rasa HealthCare
Healthy Subjects
Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.
This study will test the safety, tolerability and blood concentrations of single and multiple oral doses of PF-06751979 in health subjects and healthy elderly subjects.
- Trial name
- NCT02793232
- Testing
- PF-06751979 single dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease, Healthy Elderly
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among…
- Trial name
- NCT06546995
- Testing
- NMRA-323511
- Where
- 26 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Neumora Therapeutics, Inc.
Alzheimer Disease
A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects
A randomized, double-blind, placebo-controlled, single dose escalation phase 1 study to access the Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of SHR-1707
- Trial name
- NCT04745104
- Testing
- SHR-1707
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Alzheimer Disease, Healthy Aging
Telerehabilitation Alzheimer's Disease Feasibility (TADF)
This is a pilot RCT with equal arms: experimental arm and (wait list) control arm. All participants will be in the early stage of Alzheimer's disease and on stable medication.
- Trial name
- TADF (NCT04732182)
- Testing
- BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bright Cloud International Corp
Alzheimer's Disease
Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
This is a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.
- Trial name
- NCT01467726
- Testing
- Velusetrag
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alfasigma S.p.A.
Alzheimer Disease
Study Evaluating PAZ-417 in Healthy Young/Elderly
This study is to evaluate the safety and tolerability of single, ascending doses of PAZ-417 in healthy young and healthy elderly subjects.
- Trial name
- NCT00366288
- Testing
- PAZ-417
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Dementia, Alzheimer Disease
Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease
- Conditions
- Dementia, Alzheimer Disease, Mental Disorders
- Trial name
- NCT00034762
- Testing
- risperidone
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease
A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.
SB-742457 is a 5HT6 receptor antagonist that is in development for the symptomatic treatment of mild to moderate Alzheimer's disease . To date, all clinical trials have been conducted using a capsule formulation of SB-742457.
- Trial name
- NCT00551772
- Testing
- SB-742457
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Participants, Alzheimer's Disease Dementia
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's…
- Trial name
- NCT05644977
- Testing
- Emraclidine
- Where
- 11 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- AbbVie
Mild Cognitive Impairment
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain.
- Trial name
- NCT00040443
- Testing
- CX516
- Where
- 8 sites in United States
- Volunteers
- 175 people
- Sponsor
- RespireRx
Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.
- Trial name
- NCT00160147
- Testing
- bifeprunox
- Where
- 51 sites in United States, Czechia and 3 more
- Volunteers
- 60 people
- Sponsor
- Solvay Pharmaceuticals